How much has Novartis raised?
Novartis AG is a publicly listed company on the SIX Swiss Exchange (NOVN) and NYSE (NVS) with a market capitalization of approximately $293 billion USD as of June 2026 — making it the 54th most valuable company in the world. There are no private funding rounds; the company has been publicly financed since its formation in December 1996 via the merger of Ciba-Geigy and Sandoz, and it generates over $17B in annual free cash flow — financial scale that no startup funding round could replicate.
- Total raised (private)
- N/A — public company since December 1996
- Disclosed private rounds
- 0 — listed via merger on SIX & NYSE, Dec 20, 1996
- Market cap (June 2026)
- ~$293 billion USD (world's 54th most valuable company)
- 2025 free cash flow
- USD 17.6 billion (+8% year-over-year)
- 2025 share buybacks
- USD 9.2B cash deployed across two concurrent programs
- Notable recent acquisitions
- Anthos Therapeutics up to $3.1B (Feb 2025); Kate Therapeutics up to $1.1B (Nov 2024)
Novartis's capital events and major transactions timeline
Novartis has no private funding rounds. It was created by a public merger listing in 1996 and has grown its financial scale entirely through public equity, operating cash flows, and debt capital markets, while executing over $100B in portfolio transactions since 2018.
- December 20, 1996Public listing via Ciba-Geigy/Sandoz merger — largest corporate merger in historyNovartis begins trading on SIX Swiss Exchange (NOVN) and NYSE (NVS). Combined market cap at founding is in the tens of billions — the new company becomes the world's second-largest pharmaceutical firm at a 4.4% global market share. Both predecessor companies had 150+ year histories (Ciba to 1859, Geigy to 1758, Sandoz to 1886).
- 2018GSK Consumer Healthcare JV stake sold for $13BNovartis sells its 36.5% stake in the GSK Consumer Healthcare joint venture to GlaxoSmithKline for $13 billion in cash, returning capital to shareholders and sharpening strategic focus entirely on innovative prescription medicines.
- April 2019Alcon spinoff — ~$27B valuation at separationNovartis separates its eye-care division Alcon via a share dividend to Novartis shareholders. Alcon lists on NYSE and SIX at approximately $27 billion market cap, unlocking significant shareholder value and removing the last major non-pharma business unit from Novartis.
- December 2019AWS Strategic Collaboration Agreement established (multi-year)Novartis signs its primary cloud partnership with Amazon Web Services, committing to an enterprise-wide data and analytics platform for manufacturing, supply chain, and clinical operations. This is a capital deployment event — not an equity raise — representing significant technology investment.
- October 2023Sandoz spinoff — separate SIX listing, completing $100B+ portfolio reshapingNovartis distributes all Sandoz Group AG shares as a dividend-in-kind. Sandoz trades independently as one of Europe's largest generics companies, completing a decade-long portfolio transformation. Novartis emerges as a pure-play innovative medicines company with approximately 75,000 employees.
- November 2024Kate Therapeutics acquisition — up to $1.1BNovartis acquires Kate Therapeutics for up to $1.1 billion, adding an AAV gene therapy platform (the proprietary DELIVER capsid engineering system) targeting neuromuscular diseases including Duchenne muscular dystrophy and myotonic dystrophy type 1. Positions Novartis in the estimated $55B cell and gene therapy market by 2030.
- February 2025Anthos Therapeutics acquisition — $925M upfront, up to $3.1B totalNovartis acquires Anthos Therapeutics — originally co-founded by Novartis and Blackstone Life Sciences in 2019 — for $925 million upfront plus up to $2.15 billion in contingent milestone payments (total potential deal value $3.1B). Anthos brings abelacimab, a potential first-in-class anti-FXI monoclonal antibody in Phase III for atrial fibrillation and VTE. AZALEA-TIMI 71 data showed 62% reduction in major bleeding vs. rivaroxaban.
Sources:Novartis 2025 Full-Year ResultsAnthos Therapeutics Acquisition Press ReleaseKate Therapeutics Acquisition — BioPharma DiveSandoz Spin-off — Novartis
How much has Novartis raised in total?
Novartis has raised zero in private venture or growth equity. Unlike biotechs that depend on venture capital for survival, Novartis was created through a public company merger in December 1996 and listed directly on the SIX Swiss Exchange and NYSE simultaneously. All capital needs since formation have been met through public equity markets, investment-grade corporate bond issuances, and — most importantly — its own operating cash flows.
In 2025 alone, Novartis generated USD 19.1 billion in operating cash flows and USD 17.6 billion in free cash flow, up 8% year-over-year. These figures are possible because the company's core operating margin reached 40.1% in 2025 — among the highest sustained margins in the global pharmaceutical industry. At this scale, Novartis generates more free cash flow in a single year than many top-tier biotechs have raised across their entire corporate histories.
The company holds a strong investment-grade credit rating enabling large-scale corporate bond issuances at favorable rates. This underpins its ability to pursue multi-billion-dollar acquisitions (such as the Anthos deal totaling up to $3.1B and Kate Therapeutics up to $1.1B) without diluting equity holders. Management has signaled continued appetite for bolt-on deals in radioligand therapy, gene therapy, and cardiovascular medicine.
What drove Novartis's market cap trajectory — and how does the Entresto patent cliff fit in?
Novartis's market cap has risen from the tens of billions at founding in 1996 to approximately $293 billion in June 2026 — a more-than-tenfold increase over 30 years. Under CEO Narasimhan (from February 2018), the stock re-rated materially as the company shed lower-margin generics (Sandoz, 2023) and consumer assets (Alcon, 2019; GSK JV, 2018) and invested in high-margin innovative medicines with radioligand therapy and gene therapy upside.
A significant headwind materialized in the second half of 2025 when US generics entered the Entresto market. Entresto (sacubitril/valsartan for heart failure) had been tracking at peak US revenues approaching $3B annually and was a top-revenue product for Novartis. Following US patent litigation loss in mid-2025, generic entrants arrived in July 2025. Q4 2025 Entresto quarterly sales fell approximately 45% year-over-year, and analysts project a 50–70% total US sales decline by end-2026 as generics capture 40–60% of the market.
The stock market had largely priced in this cliff over 2024–2025, which is why Novartis's market cap has remained resilient at ~$293B. Accelerating growth in Kisqali (USD 4.8B, +57% cc in 2025), Pluvicto (+42% cc), Kesimpta (+36% cc), and Scemblix (+85% cc) more than offset Entresto erosion in operating profit terms. For Q1 2026, net sales fell 5% in constant currencies due to Entresto generic headwinds, but management reaffirmed full-year 2026 guidance of low-single-digit reported sales growth.
Who are Novartis's shareholders and investors?
As a publicly listed company, Novartis's largest shareholders are institutional asset managers. The company itself holds treasury shares as a result of its buyback programs — Novartis deployed USD 9.2 billion in total cash on share repurchases in 2025 across the completed USD 15B program (closed July 2025) and the new USD 10B program (launched July 2025). Major global passive and active fund managers including BlackRock, Vanguard, and Capital Group hold single-digit percentage stakes.
Swiss institutional investors, cantonal banks, and public pension funds hold meaningful positions as well. There are no controlling family or founder shareholders, nor any private equity sponsors. Novartis's ADRs (NYSE: NVS) are widely held by US retail and institutional investors, giving the company a diversified and globally liquid ownership structure.
What Novartis's financial scale means if you sell to them
Novartis's USD 54.5B revenue base and USD 17.6B annual free cash flow signal an enterprise with sophisticated procurement, multi-year technology contracts, and a genuine appetite for large vendor relationships. The December 2025 Salesforce Agentforce Life Sciences deal (a 5-year global rollout) and the long-standing AWS Strategic Collaboration Agreement illustrate Novartis's willingness to sign large-scale SaaS, cloud, and platform deals.
Vendors should expect a formal, structured procurement process: RFP issuance, IT security review, legal review, and compliance sign-off are standard for any significant technology vendor. Sales cycles are long — typically 12–24 months for enterprise technology — but contract values are commensurately substantial. Key budget-holding personas are President Operations (manufacturing, supply chain, industrial IoT), President US (CRM, HCP engagement, commercial analytics), CFO (ERP, finance systems), and President Development (clinical data, AI/ML in drug discovery).
The 2025 Anthos ($925M upfront) and Kate Therapeutics (up to $1.1B) acquisitions confirm active M&A budget. Vendors in cardiovascular data, RLT process control, gene therapy manufacturing, clinical AI, and radioligand supply chain management are in active buying cycles and should approach through Novartis's R&D, Operations, and Business Development functions.
As of June 2026.Sources:Novartis 2025 Full-Year ResultsNovartis Market Cap — Companies Market CapAnthos Therapeutics AcquisitionNovartis Investor Relations
Novartis — frequently asked questions
